Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:30 a.m. ET in New York.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:30 a.m. ET in New York.
A live webcast will stream via the investor section of www.beamtx.com and remain archived for 60 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BEAM
In the May 13 session, BEAM gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- License & collaboration revenue
- $31.7 million
- Q1 2026, per 10-Q and 8-K
- Prior-year revenue
- $7.5 million
- Q1 2025 comparison, per filings
- R&D spending
- $104.5 million
- Q1 2026 research and development expense
- Net loss
- $94.3 million
- Q1 2026 net loss, per filings
- EPS
- $0.91 per share
- Q1 2026 loss per share
- Cash and securities
- $1.2 billion
- Quarter-end cash, equivalents and marketable securities
- Credit facility draw
- $100 million
- Initial draw from facility maturing in 2033
- Vanguard ownership
- 5.02%
- Beneficial ownership of common stock per Schedule 13G
Historical Context
-
Updated BEACON biomarker data for risto-cel in sickle cell disease.
-
Q1 2026 results plus BEAM-302 dose selection and BLA timing for risto-cel.
-
NEJM publication of BEACON Phase 1/2 data for risto-cel in SCD.
-
Updated Phase 1/2 BEAM-302 AATD data supporting advancement to pivotal stage.
-
Q4 2025 results, new PKU program BEAM-304, and financing facility announcement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
base editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.